Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Paris
Clinical trial register · France

Clinical Trials in Paris, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9697 matching records held by the registry are in this view. Synced 26 Oct 2026, 03:20 UTC
9697
Studies in scope
all four open statuses
6025
Recruiting now
open to new participants
1033
Lead sponsors
across recruiting studies
Top sites
Paris 46 Marseille 37 Toulouse 32 Bordeaux 29 Lille 23
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Assistance Publique - Hôpitaux de Paris602 Novartis Pharmaceuticals68 Fondation Ophtalmologique Adolphe de Rothschild66 AstraZeneca64 Institut National de la Santé Et de la Recherche Médicale, France63 Clear sponsor filter
Site location
Paris46 Marseille37 Toulouse32 Bordeaux29 Lille23
All 72 locations
Target enrolment
to

Trials with a site in Paris

46 of 9697 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
340
Paris
2026-05-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Strasbourg, Brest, Caen, Chambray-lès-Tours, Bordeaux, Toulouse, Paris
2026-01-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
570
Bordeaux, Toulouse, Nantes, Lyon, Bobigny, Paris
2025-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Limoges, Paris
2025-12-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Marseille, Caen, Vandœuvre-lès-Nancy, Pau, Chambéry, Amiens, Paris
2025-10-08
Active, closed
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
NCT07044297Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
DrugMK-8527
Merck Sharp & Dohme LLC
Phase 3
4,390
Paris
2025-07-31
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
298
Brest, Lille, Paris
2025-07-30
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Lyon, Bordeaux, Toulon, Paris
2025-06-09
Recruiting
Merck Sharp & Dohme LLC
Phase 2
160
Nice, Paris, Villejuif
2025-05-29
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
Bordeaux, Marseille, Nantes, Lyon, Paris
2025-05-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Lille, Bordeaux, Pierre-Bénite, Caen, Plérin, Toulouse, Chambray-lès-Tours, Paris
2025-04-09
Active, closed
Merck Sharp & Dohme LLC
Phase 2
160
Caen, Montpellier, Villejuif, Paris
2025-04-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Lyon, Limoges, Montpellier, Saint-Herblain, Reims, Rouen, Toulon, Paris
2025-03-16
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
DrugIntismeran autogene
Merck Sharp & Dohme LLC
Phase 2
308
Dijon, Bordeaux, Rouen, Suresnes, Paris
2025-03-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Dijon, Saint Priest En Jarez, Pierre-Bénite, Paris
2024-12-02
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Caen, Tours, Besançon, Saint-Herblain, Lille, Lyon, Paris, Villejuif
2024-10-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
160
Brest, Lille, Paris
2024-09-20
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Brest, Lille, Paris
2024-08-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Strasbourg, Marseille, Paris, Villejuif
2024-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Marseille, Vantoux, Angers, Avignon, La Roche-sur-Yon, Paris
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
Bordeaux, Strasbourg, Paris, Villejuif
2024-05-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
473
Bordeaux, Lyon, Caen, Toulouse, Lille, Rennes, Poitiers, Paris
2024-05-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Lyon, Caen, Montpellier, Nantes, Poitiers, Paris
2024-04-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
272
Lyon Cedex08, Besançon, Toulouse, Paris, Villejuif
2024-04-10
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
230
Toulouse, Angers, Lille, Paris, Villejuif
2024-03-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Lille, Strasbourg, Nîmes, Rennes, Clermont-Ferrand, Bayonne, Villejuif, Paris
2023-12-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Rennes, Tours, Limoges, Vandœuvre-lès-Nancy, Roubaix, Pierre-Bénite, Paris
2023-12-31
Active, closed
Merck Sharp & Dohme LLC
Phase 2
147
Lyon Cedex08, Caen, Limoges, Toulon, Paris
2023-12-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Strasbourg, Pessac, Marseille, Caen, Montpellier, Angers, Clermont-Ferrand, Paris
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Bordeaux, Lyon Cedex08, Rouen, Paris
2023-11-12
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
390
Bordeaux, Dijon, Toulouse, Pierre-Bénite, Paris
2023-06-23
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
342
Pessac, Nantes, Lille, Marseille, Paris
2023-05-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
537
Nice, Tourcoing, Paris, Bobigny
2023-03-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
377
Quimper, Tours, Paris
2023-02-14
Recruiting
Merck Sharp & Dohme LLC
Phase 2
42
Toulouse, Marseille, Paris
2023-01-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Lyon, Strasbourg, Rennes, Chambray-lès-Tours, Besançon, Angers, Paris, Villejuif
2022-03-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Pierre-Bénite, Paris
2022-01-14
Recruiting
Merck Sharp & Dohme LLC
Phase 2
355
Strasbourg, Lyon, Marseille, Le Kremlin-Bicêtre, Paris, Villejuif
2021-08-12
Active, closed
Merck Sharp & Dohme LLC
Phase 2
302
Marseille, Dijon, Toulouse, Lille, Poitiers, Paris
2021-06-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Marseille, Besançon, Toulouse, Limoges, Beuvry, Angers, Pierre-Bénite, Paris
2021-04-14
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Nice, Pierre-Bénite, Marseille, Le Chesnay, Paris
2021-04-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
Avignon, Amiens, Paris
2020-05-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
6,033
Dijon, Montpellier, Rennes, Nantes, Paris
2020-02-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Nice, Marseille, Toulouse, Villejuif, Avignon, Paris
2018-12-17
Active, closed
Merck Sharp & Dohme LLC
Phase 2
340
Lyon, Marseille, Bordeaux, Lille, Villejuif, Paris
2018-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
370
Paris
2015-03-19
Rows per page Showing 1–46 of 46
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 October 2026. https://priyalifescience.com/clinical-trials-france/city/paris

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,697 studies in total at the last sync on 26 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 46 of those studies with a site in Paris that also match the filters currently applied.

How many clinical trials are recruiting in Paris?

25 of the 46 studies on this page are recruiting new participants as of the 26 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 21 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Paris), 46 studies
PhaseStudiesRecruitingShare
Phase 322947.8%
Phase 212626.1%
Phase 1/28617.4%
Phase 2/3448.7%

Most active sponsors

Lead sponsors with the most studies (Paris)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC4625
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.